Table of Content

1 Anti-CD31 Antibody Market Overview
1.1 Product Overview and Scope of Anti-CD31 Antibody
1.2 Anti-CD31 Antibody Segment by Type
1.2.1 Global Anti-CD31 Antibody Market Value Comparison by Type (2023-2033)
1.2.2 Monoclonal
1.2.3 Polyclonal
1.3 Anti-CD31 Antibody Segment by Application
1.3.1 Global Anti-CD31 Antibody Market Value by Application: (2023-2033)
1.3.2 Immunochemistry
1.3.3 Immunofluorescence
1.3.4 Immunoprecipitation
1.3.5 Western Blot
1.3.6 Others
1.4 Global Anti-CD31 Antibody Market Size Estimates and Forecasts
1.4.1 Global Anti-CD31 Antibody Revenue 2018-2033
1.4.2 Global Anti-CD31 Antibody Sales 2018-2033
1.4.3 Global Anti-CD31 Antibody Market Average Price (2018-2033)
1.5 Assumptions and Limitations
2 Anti-CD31 Antibody Market Competition by Manufacturers
2.1 Global Anti-CD31 Antibody Sales Market Share by Manufacturers (2018-2023)
2.2 Global Anti-CD31 Antibody Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Anti-CD31 Antibody Average Price by Manufacturers (2018-2023)
2.4 Global Anti-CD31 Antibody Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Anti-CD31 Antibody, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-CD31 Antibody, Product Type & Application
2.7 Anti-CD31 Antibody Market Competitive Situation and Trends
2.7.1 Anti-CD31 Antibody Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anti-CD31 Antibody Players Market Share by Revenue
2.7.3 Global Anti-CD31 Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-CD31 Antibody Retrospective Market Scenario by Region
3.1 Global Anti-CD31 Antibody Market Size by Region: 2018 Versus 2022 Versus 2033
3.2 Global Anti-CD31 Antibody Global Anti-CD31 Antibody Sales by Region: 2018-2033
3.2.1 Global Anti-CD31 Antibody Sales by Region: 2018-2023
3.2.2 Global Anti-CD31 Antibody Sales by Region: 2024-2033
3.3 Global Anti-CD31 Antibody Global Anti-CD31 Antibody Revenue by Region: 2018-2033
3.3.1 Global Anti-CD31 Antibody Revenue by Region: 2018-2023
3.3.2 Global Anti-CD31 Antibody Revenue by Region: 2024-2033
3.4 North America Anti-CD31 Antibody Market Facts & Figures by Country
3.4.1 North America Anti-CD31 Antibody Market Size by Country: 2018 VS 2022 VS 2033
3.4.2 North America Anti-CD31 Antibody Sales by Country (2018-2033)
3.4.3 North America Anti-CD31 Antibody Revenue by Country (2018-2033)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-CD31 Antibody Market Facts & Figures by Country
3.5.1 Europe Anti-CD31 Antibody Market Size by Country: 2018 VS 2022 VS 2033
3.5.2 Europe Anti-CD31 Antibody Sales by Country (2018-2033)
3.5.3 Europe Anti-CD31 Antibody Revenue by Country (2018-2033)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-CD31 Antibody Market Facts & Figures by Country
3.6.1 Asia Pacific Anti-CD31 Antibody Market Size by Country: 2018 VS 2022 VS 2033
3.6.2 Asia Pacific Anti-CD31 Antibody Sales by Country (2018-2033)
3.6.3 Asia Pacific Anti-CD31 Antibody Revenue by Country (2018-2033)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Anti-CD31 Antibody Market Facts & Figures by Country
3.7.1 Latin America Anti-CD31 Antibody Market Size by Country: 2018 VS 2022 VS 2033
3.7.2 Latin America Anti-CD31 Antibody Sales by Country (2018-2033)
3.7.3 Latin America Anti-CD31 Antibody Revenue by Country (2018-2033)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Anti-CD31 Antibody Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-CD31 Antibody Market Size by Country: 2018 VS 2022 VS 2033
3.8.2 Middle East and Africa Anti-CD31 Antibody Sales by Country (2018-2033)
3.8.3 Middle East and Africa Anti-CD31 Antibody Revenue by Country (2018-2033)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-CD31 Antibody Sales by Type (2018-2033)
4.1.1 Global Anti-CD31 Antibody Sales by Type (2018-2023)
4.1.2 Global Anti-CD31 Antibody Sales by Type (2024-2033)
4.1.3 Global Anti-CD31 Antibody Sales Market Share by Type (2018-2033)
4.2 Global Anti-CD31 Antibody Revenue by Type (2018-2033)
4.2.1 Global Anti-CD31 Antibody Revenue by Type (2018-2023)
4.2.2 Global Anti-CD31 Antibody Revenue by Type (2024-2033)
4.2.3 Global Anti-CD31 Antibody Revenue Market Share by Type (2018-2033)
4.3 Global Anti-CD31 Antibody Price by Type (2018-2033)
5 Segment by Application
5.1 Global Anti-CD31 Antibody Sales by Application (2018-2033)
5.1.1 Global Anti-CD31 Antibody Sales by Application (2018-2023)
5.1.2 Global Anti-CD31 Antibody Sales by Application (2024-2033)
5.1.3 Global Anti-CD31 Antibody Sales Market Share by Application (2018-2033)
5.2 Global Anti-CD31 Antibody Revenue by Application (2018-2033)
5.2.1 Global Anti-CD31 Antibody Revenue by Application (2018-2023)
5.2.2 Global Anti-CD31 Antibody Revenue by Application (2024-2033)
5.2.3 Global Anti-CD31 Antibody Revenue Market Share by Application (2018-2033)
5.3 Global Anti-CD31 Antibody Price by Application (2018-2033)
6 Key Companies Profiled
6.1 BosterBio
6.1.1 BosterBio Corporation Information
6.1.2 BosterBio Description and Business Overview
6.1.3 BosterBio Anti-CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.1.4 BosterBio Anti-CD31 Antibody Product Portfolio
6.1.5 BosterBio Recent Developments/Updates
6.2 Bio-Rad
6.2.1 Bio-Rad Corporation Information
6.2.2 Bio-Rad Description and Business Overview
6.2.3 Bio-Rad Anti-CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Bio-Rad Anti-CD31 Antibody Product Portfolio
6.2.5 Bio-Rad Recent Developments/Updates
6.3 BD Biosciences
6.3.1 BD Biosciences Corporation Information
6.3.2 BD Biosciences Description and Business Overview
6.3.3 BD Biosciences Anti-CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.3.4 BD Biosciences Anti-CD31 Antibody Product Portfolio
6.3.5 BD Biosciences Recent Developments/Updates
6.4 Abcam
6.4.1 Abcam Corporation Information
6.4.2 Abcam Description and Business Overview
6.4.3 Abcam Anti-CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Abcam Anti-CD31 Antibody Product Portfolio
6.4.5 Abcam Recent Developments/Updates
6.5 RayBiotech
6.5.1 RayBiotech Corporation Information
6.5.2 RayBiotech Description and Business Overview
6.5.3 RayBiotech Anti-CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.5.4 RayBiotech Anti-CD31 Antibody Product Portfolio
6.5.5 RayBiotech Recent Developments/Updates
6.6 GeneTex
6.6.1 GeneTex Corporation Information
6.6.2 GeneTex Description and Business Overview
6.6.3 GeneTex Anti-CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.6.4 GeneTex Anti-CD31 Antibody Product Portfolio
6.6.5 GeneTex Recent Developments/Updates
6.7 BioLegend
6.6.1 BioLegend Corporation Information
6.6.2 BioLegend Description and Business Overview
6.6.3 BioLegend Anti-CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.4.4 BioLegend Anti-CD31 Antibody Product Portfolio
6.7.5 BioLegend Recent Developments/Updates
6.8 BMA Biomedicals
6.8.1 BMA Biomedicals Corporation Information
6.8.2 BMA Biomedicals Description and Business Overview
6.8.3 BMA Biomedicals Anti-CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.8.4 BMA Biomedicals Anti-CD31 Antibody Product Portfolio
6.8.5 BMA Biomedicals Recent Developments/Updates
6.9 Bethyl Laboratories
6.9.1 Bethyl Laboratories Corporation Information
6.9.2 Bethyl Laboratories Description and Business Overview
6.9.3 Bethyl Laboratories Anti-CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Bethyl Laboratories Anti-CD31 Antibody Product Portfolio
6.9.5 Bethyl Laboratories Recent Developments/Updates
6.10 SouthernBiotech
6.10.1 SouthernBiotech Corporation Information
6.10.2 SouthernBiotech Description and Business Overview
6.10.3 SouthernBiotech Anti-CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.10.4 SouthernBiotech Anti-CD31 Antibody Product Portfolio
6.10.5 SouthernBiotech Recent Developments/Updates
6.11 Elabscience Biotechnology Inc
6.11.1 Elabscience Biotechnology Inc Corporation Information
6.11.2 Elabscience Biotechnology Inc Anti-CD31 Antibody Description and Business Overview
6.11.3 Elabscience Biotechnology Inc Anti-CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Elabscience Biotechnology Inc Anti-CD31 Antibody Product Portfolio
6.11.5 Elabscience Biotechnology Inc Recent Developments/Updates
6.12 Merck
6.12.1 Merck Corporation Information
6.12.2 Merck Anti-CD31 Antibody Description and Business Overview
6.12.3 Merck Anti-CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Merck Anti-CD31 Antibody Product Portfolio
6.12.5 Merck Recent Developments/Updates
6.13 Leica Biosystems
6.13.1 Leica Biosystems Corporation Information
6.13.2 Leica Biosystems Anti-CD31 Antibody Description and Business Overview
6.13.3 Leica Biosystems Anti-CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Leica Biosystems Anti-CD31 Antibody Product Portfolio
6.13.5 Leica Biosystems Recent Developments/Updates
6.14 Beijing Solarbio Science & Technology
6.14.1 Beijing Solarbio Science & Technology Corporation Information
6.14.2 Beijing Solarbio Science & Technology Anti-CD31 Antibody Description and Business Overview
6.14.3 Beijing Solarbio Science & Technology Anti-CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Beijing Solarbio Science & Technology Anti-CD31 Antibody Product Portfolio
6.14.5 Beijing Solarbio Science & Technology Recent Developments/Updates
6.15 Wuhan Fine Biotech
6.15.1 Wuhan Fine Biotech Corporation Information
6.15.2 Wuhan Fine Biotech Anti-CD31 Antibody Description and Business Overview
6.15.3 Wuhan Fine Biotech Anti-CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Wuhan Fine Biotech Anti-CD31 Antibody Product Portfolio
6.15.5 Wuhan Fine Biotech Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-CD31 Antibody Industry Chain Analysis
7.2 Anti-CD31 Antibody Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-CD31 Antibody Production Mode & Process
7.4 Anti-CD31 Antibody Sales and Marketing
7.4.1 Anti-CD31 Antibody Sales Channels
7.4.2 Anti-CD31 Antibody Distributors
7.5 Anti-CD31 Antibody Customers
8 Anti-CD31 Antibody Market Dynamics
8.1 Anti-CD31 Antibody Industry Trends
8.2 Anti-CD31 Antibody Market Drivers
8.3 Anti-CD31 Antibody Market Challenges
8.4 Anti-CD31 Antibody Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Anti-CD31 Antibody Market Value Comparison by Type (2023-2033) & (US$ Million)
Table 2. Global Anti-CD31 Antibody Market Value Comparison by Application (2023-2033) & (US$ Million)
Table 3. Global Anti-CD31 Antibody Market Competitive Situation by Manufacturers in 2022
Table 4. Global Anti-CD31 Antibody Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Anti-CD31 Antibody Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Anti-CD31 Antibody Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Anti-CD31 Antibody Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Anti-CD31 Antibody Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Anti-CD31 Antibody, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Anti-CD31 Antibody, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Anti-CD31 Antibody, Product Type & Application
Table 12. Global Key Manufacturers of Anti-CD31 Antibody, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Anti-CD31 Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-CD31 Antibody as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-CD31 Antibody Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 17. Global Anti-CD31 Antibody Sales by Region (2018-2023) & (K Units)
Table 18. Global Anti-CD31 Antibody Sales Market Share by Region (2018-2023)
Table 19. Global Anti-CD31 Antibody Sales by Region (2024-2033) & (K Units)
Table 20. Global Anti-CD31 Antibody Sales Market Share by Region (2024-2033)
Table 21. Global Anti-CD31 Antibody Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Anti-CD31 Antibody Revenue Market Share by Region (2018-2023)
Table 23. Global Anti-CD31 Antibody Revenue by Region (2024-2033) & (US$ Million)
Table 24. Global Anti-CD31 Antibody Revenue Market Share by Region (2024-2033)
Table 25. North America Anti-CD31 Antibody Revenue by Country: 2018 VS 2022 VS 2033 (US$ Million)
Table 26. North America Anti-CD31 Antibody Sales by Country (2018-2023) & (K Units)
Table 27. North America Anti-CD31 Antibody Sales by Country (2024-2033) & (K Units)
Table 28. North America Anti-CD31 Antibody Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Anti-CD31 Antibody Revenue by Country (2024-2033) & (US$ Million)
Table 30. Europe Anti-CD31 Antibody Revenue by Country: 2018 VS 2022 VS 2033 (US$ Million)
Table 31. Europe Anti-CD31 Antibody Sales by Country (2018-2023) & (K Units)
Table 32. Europe Anti-CD31 Antibody Sales by Country (2024-2033) & (K Units)
Table 33. Europe Anti-CD31 Antibody Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Anti-CD31 Antibody Revenue by Country (2024-2033) & (US$ Million)
Table 35. Asia Pacific Anti-CD31 Antibody Revenue by Region: 2018 VS 2022 VS 2033 (US$ Million)
Table 36. Asia Pacific Anti-CD31 Antibody Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Anti-CD31 Antibody Sales by Region (2024-2033) & (K Units)
Table 38. Asia Pacific Anti-CD31 Antibody Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Anti-CD31 Antibody Revenue by Region (2024-2033) & (US$ Million)
Table 40. Latin America Anti-CD31 Antibody Revenue by Country: 2018 VS 2022 VS 2033 (US$ Million)
Table 41. Latin America Anti-CD31 Antibody Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Anti-CD31 Antibody Sales by Country (2024-2033) & (K Units)
Table 43. Latin America Anti-CD31 Antibody Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Anti-CD31 Antibody Revenue by Country (2024-2033) & (US$ Million)
Table 45. Middle East & Africa Anti-CD31 Antibody Revenue by Country: 2018 VS 2022 VS 2033 (US$ Million)
Table 46. Middle East & Africa Anti-CD31 Antibody Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Anti-CD31 Antibody Sales by Country (2024-2033) & (K Units)
Table 48. Middle East & Africa Anti-CD31 Antibody Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Anti-CD31 Antibody Revenue by Country (2024-2033) & (US$ Million)
Table 50. Global Anti-CD31 Antibody Sales (K Units) by Type (2018-2023)
Table 51. Global Anti-CD31 Antibody Sales (K Units) by Type (2024-2033)
Table 52. Global Anti-CD31 Antibody Sales Market Share by Type (2018-2023)
Table 53. Global Anti-CD31 Antibody Sales Market Share by Type (2024-2033)
Table 54. Global Anti-CD31 Antibody Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Anti-CD31 Antibody Revenue (US$ Million) by Type (2024-2033)
Table 56. Global Anti-CD31 Antibody Revenue Market Share by Type (2018-2023)
Table 57. Global Anti-CD31 Antibody Revenue Market Share by Type (2024-2033)
Table 58. Global Anti-CD31 Antibody Price (US$/Unit) by Type (2018-2023)
Table 59. Global Anti-CD31 Antibody Price (US$/Unit) by Type (2024-2033)
Table 60. Global Anti-CD31 Antibody Sales (K Units) by Application (2018-2023)
Table 61. Global Anti-CD31 Antibody Sales (K Units) by Application (2024-2033)
Table 62. Global Anti-CD31 Antibody Sales Market Share by Application (2018-2023)
Table 63. Global Anti-CD31 Antibody Sales Market Share by Application (2024-2033)
Table 64. Global Anti-CD31 Antibody Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Anti-CD31 Antibody Revenue (US$ Million) by Application (2024-2033)
Table 66. Global Anti-CD31 Antibody Revenue Market Share by Application (2018-2023)
Table 67. Global Anti-CD31 Antibody Revenue Market Share by Application (2024-2033)
Table 68. Global Anti-CD31 Antibody Price (US$/Unit) by Application (2018-2023)
Table 69. Global Anti-CD31 Antibody Price (US$/Unit) by Application (2024-2033)
Table 70. BosterBio Corporation Information
Table 71. BosterBio Description and Business Overview
Table 72. BosterBio Anti-CD31 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. BosterBio Anti-CD31 Antibody Product
Table 74. BosterBio Recent Developments/Updates
Table 75. Bio-Rad Corporation Information
Table 76. Bio-Rad Description and Business Overview
Table 77. Bio-Rad Anti-CD31 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Bio-Rad Anti-CD31 Antibody Product
Table 79. Bio-Rad Recent Developments/Updates
Table 80. BD Biosciences Corporation Information
Table 81. BD Biosciences Description and Business Overview
Table 82. BD Biosciences Anti-CD31 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. BD Biosciences Anti-CD31 Antibody Product
Table 84. BD Biosciences Recent Developments/Updates
Table 85. Abcam Corporation Information
Table 86. Abcam Description and Business Overview
Table 87. Abcam Anti-CD31 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Abcam Anti-CD31 Antibody Product
Table 89. Abcam Recent Developments/Updates
Table 90. RayBiotech Corporation Information
Table 91. RayBiotech Description and Business Overview
Table 92. RayBiotech Anti-CD31 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. RayBiotech Anti-CD31 Antibody Product
Table 94. RayBiotech Recent Developments/Updates
Table 95. GeneTex Corporation Information
Table 96. GeneTex Description and Business Overview
Table 97. GeneTex Anti-CD31 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. GeneTex Anti-CD31 Antibody Product
Table 99. GeneTex Recent Developments/Updates
Table 100. BioLegend Corporation Information
Table 101. BioLegend Description and Business Overview
Table 102. BioLegend Anti-CD31 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. BioLegend Anti-CD31 Antibody Product
Table 104. BioLegend Recent Developments/Updates
Table 105. BMA Biomedicals Corporation Information
Table 106. BMA Biomedicals Description and Business Overview
Table 107. BMA Biomedicals Anti-CD31 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. BMA Biomedicals Anti-CD31 Antibody Product
Table 109. BMA Biomedicals Recent Developments/Updates
Table 110. Bethyl Laboratories Corporation Information
Table 111. Bethyl Laboratories Description and Business Overview
Table 112. Bethyl Laboratories Anti-CD31 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Bethyl Laboratories Anti-CD31 Antibody Product
Table 114. Bethyl Laboratories Recent Developments/Updates
Table 115. SouthernBiotech Corporation Information
Table 116. SouthernBiotech Description and Business Overview
Table 117. SouthernBiotech Anti-CD31 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. SouthernBiotech Anti-CD31 Antibody Product
Table 119. SouthernBiotech Recent Developments/Updates
Table 120. Elabscience Biotechnology Inc Corporation Information
Table 121. Elabscience Biotechnology Inc Description and Business Overview
Table 122. Elabscience Biotechnology Inc Anti-CD31 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Elabscience Biotechnology Inc Anti-CD31 Antibody Product
Table 124. Elabscience Biotechnology Inc Recent Developments/Updates
Table 125. Merck Corporation Information
Table 126. Merck Description and Business Overview
Table 127. Merck Anti-CD31 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Merck Anti-CD31 Antibody Product
Table 129. Merck Recent Developments/Updates
Table 130. Leica Biosystems Corporation Information
Table 131. Leica Biosystems Description and Business Overview
Table 132. Leica Biosystems Anti-CD31 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Leica Biosystems Anti-CD31 Antibody Product
Table 134. Leica Biosystems Recent Developments/Updates
Table 135. Beijing Solarbio Science & Technology Corporation Information
Table 136. Beijing Solarbio Science & Technology Description and Business Overview
Table 137. Beijing Solarbio Science & Technology Anti-CD31 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Beijing Solarbio Science & Technology Anti-CD31 Antibody Product
Table 139. Beijing Solarbio Science & Technology Recent Developments/Updates
Table 140. Wuhan Fine Biotech Corporation Information
Table 141. Wuhan Fine Biotech Description and Business Overview
Table 142. Wuhan Fine Biotech Anti-CD31 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 143. Wuhan Fine Biotech Anti-CD31 Antibody Product
Table 144. Wuhan Fine Biotech Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Anti-CD31 Antibody Distributors List
Table 148. Anti-CD31 Antibody Customers List
Table 149. Anti-CD31 Antibody Market Trends
Table 150. Anti-CD31 Antibody Market Drivers
Table 151. Anti-CD31 Antibody Market Challenges
Table 152. Anti-CD31 Antibody Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Anti-CD31 Antibody
Figure 2. Global Anti-CD31 Antibody Market Value Comparison by Type (2023-2033) & (US$ Million)
Figure 3. Global Anti-CD31 Antibody Market Share by Type in 2022 & 2033
Figure 4. Monoclonal Product Picture
Figure 5. Polyclonal Product Picture
Figure 6. Global Anti-CD31 Antibody Market Value Comparison by Application (2023-2033) & (US$ Million)
Figure 7. Global Anti-CD31 Antibody Market Share by Application in 2022 & 2033
Figure 8. Immunochemistry
Figure 9. Immunofluorescence
Figure 10. Immunoprecipitation
Figure 11. Western Blot
Figure 12. Others
Figure 13. Global Anti-CD31 Antibody Revenue, (US$ Million), 2018 VS 2022 VS 2033
Figure 14. Global Anti-CD31 Antibody Market Size (2018-2033) & (US$ Million)
Figure 15. Global Anti-CD31 Antibody Sales (2018-2033) & (K Units)
Figure 16. Global Anti-CD31 Antibody Average Price (US$/Unit) & (2018-2033)
Figure 17. Anti-CD31 Antibody Report Years Considered
Figure 18. Anti-CD31 Antibody Sales Share by Manufacturers in 2022
Figure 19. Global Anti-CD31 Antibody Revenue Share by Manufacturers in 2022
Figure 20. The Global 5 and 10 Largest Anti-CD31 Antibody Players: Market Share by Revenue in 2022
Figure 21. Anti-CD31 Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 22. Global Anti-CD31 Antibody Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Figure 23. North America Anti-CD31 Antibody Sales Market Share by Country (2018-2033)
Figure 24. North America Anti-CD31 Antibody Revenue Market Share by Country (2018-2033)
Figure 25. United States Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 26. Canada Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 27. Europe Anti-CD31 Antibody Sales Market Share by Country (2018-2033)
Figure 28. Europe Anti-CD31 Antibody Revenue Market Share by Country (2018-2033)
Figure 29. Germany Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 30. France Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 31. U.K. Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 32. Italy Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 33. Russia Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 34. Asia Pacific Anti-CD31 Antibody Sales Market Share by Region (2018-2033)
Figure 35. Asia Pacific Anti-CD31 Antibody Revenue Market Share by Region (2018-2033)
Figure 36. China Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 37. Japan Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 38. South Korea Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 39. India Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 40. Australia Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 41. China Taiwan Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 42. Southeast Asia Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 43. Latin America Anti-CD31 Antibody Sales Market Share by Country (2018-2033)
Figure 44. Latin America Anti-CD31 Antibody Revenue Market Share by Country (2018-2033)
Figure 45. Mexico Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 46. Brazil Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 47. Argentina Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 48. Colombia Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 49. Middle East & Africa Anti-CD31 Antibody Sales Market Share by Country (2018-2033)
Figure 50. Middle East & Africa Anti-CD31 Antibody Revenue Market Share by Country (2018-2033)
Figure 51. Turkey Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 52. Saudi Arabia Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 53. UAE Anti-CD31 Antibody Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 54. Global Sales Market Share of Anti-CD31 Antibody by Type (2018-2033)
Figure 55. Global Revenue Market Share of Anti-CD31 Antibody by Type (2018-2033)
Figure 56. Global Anti-CD31 Antibody Price (US$/Unit) by Type (2018-2033)
Figure 57. Global Sales Market Share of Anti-CD31 Antibody by Application (2018-2033)
Figure 58. Global Revenue Market Share of Anti-CD31 Antibody by Application (2018-2033)
Figure 59. Global Anti-CD31 Antibody Price (US$/Unit) by Application (2018-2033)
Figure 60. Anti-CD31 Antibody Value Chain
Figure 61. Anti-CD31 Antibody Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed